• Expertise
  • Ingredient Solutions
  • Applications
  • Resources
    Resources
  • PLT People & Planet
  • About
    About

    Our international network, passionate team of experts and extensive industry knowledge is what sets us apart.

    Seth circle headshot
    Seth Flowerman
    President and CEO
Clinical Research

Pharmacokinetics of Menaquinone-7 (Vitamin K2) in Healthy Volunteers

Citation:  Knapen MJH, Vermeer C, Braam LAJLM, Theuwissen E. Pharmacokinetics of Menaquinone-7 (Vitamin K2) in Healthy Volunteers. J Clin Trials 2014;4:2. doi: 10.4172/2167-0870.1000160

Abstract:

Objective: Because of the wide-spread use of menaquinone-7 (MK-7, a form of vitamin K2) supplements, we have investigated its pharmacokinetics following a single intake from various formulations.

Methods: Different formulations were compared in four human intervention studies with healthy volunteers. Participants received either capsules (filling material: linseed oil; MK-7 carrier material: sunflower oil) or tablets (filling material: dicalcium phosphate dehydrate (DCPD) and cellulose; MK-7 carriers: casein, Arabic gum, or sunflower oil). MK-7-absorption profiles (24 h area-under-the-curves, 24 h AUCs) were used to compare intestinal absorption. Special attention was given to intra- and inter-subject variability.

Results: The absorption (time-to-peak) of MK-7 from tablets was slower than from capsules, 6 h as compared to 2 h-4 h, respectively. Probably, the oily matrix of the capsules released the lipophilic MK-7 more rapidly than the powder matrix of the tablets. We further found a dose response relationship for MK-7 at 24 h after the single-dose intakes (at group level). As compared to baseline, circulating MK-7 levels were still elevated at 24 h after intake, confirming the relatively long half-life of MK-7. The different MK-7 carrier materials showed similar 24 h-absorption profiles, indicating that the carrier was not influencing MK-7 absorption. Next to high intra-subject variability, high inter-subject variability
was seen in the different studies. This was found for both, peak height and for total absorption (measured as 24 h-AUC). While some subjects showed a linear dose-response relation, other subjects had similar 24 h-AUCs after intake of MK-7 at different dosages

Conclusions: We have demonstrated that on a group level the bioavailability (24 h absorption) of MK-7 was similar for capsules and tablets, and also for the different MK-7 carriers. MK-7 absorption from the various formulations showed high intra- and inter-individual differences.

Request a Copy of The Clinical Trial